Journal
NATURE MEDICINE
Volume 10, Issue 11, Pages 1187-1189Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm1127
Keywords
-
Funding
- NCI NIH HHS [1R01CA101859-01, R01CA90833] Funding Source: Medline
Ask authors/readers for more resources
We studied the effects of Lyn ablation on the survival of drug-resistant chronic myelogenous leukemia (CML) blast crisis cells using siRNA. Lyn siRNA reduced Lyn protein in both normal hematopoietic cells and BCR-ABL1-expressing (BCR-ABL1(+)) blasts by 80-95%. Within 48 h, siRNA-treated BCR-ABL1(+) blasts underwent apoptosis, whereas normal cells remained viable. This increased dependence on Lyn signaling for BCR-ABL1(+) blast survival provides the basis for rational treatment of drug-resistant CML blast crisis, particularly when lymphoid in nature.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available